key: cord-0761844-8nkh2j10
authors: Abrams, Elissa M.; Jordan, Kamyron; Szefler, Stanley J.
title: School Asthma Care During COVID-19: What we have learned, and what we are learning
date: 2021-11-27
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2021.11.020
sha: 085396d0e5c158b93109ba11d62da6d90fb67602
doc_id: 761844
cord_uid: 8nkh2j10

The focus of this article is to review school asthma care during COVID-19. Asthma is listed as a risk factor in some guidelines, although children with asthma appear to not be at increased risk of severe respiratory outcomes compared to children without asthma during the pandemic. Differentiating COVID-19 from allergic disease is very difficult to do in the school-aged children. For school management, there is firm evidence that masks do not exacerbate underlying lung conditions including asthma and evidence to date supports that children with asthma can learn in-person at school as they do not appear to be at increased risk of COVID-19 morbidity or mortality. For children and adolescents, the COVID-19 vaccine has been demonstrated to be safe and well tolerated. School asthma management includes remaining on prescribed asthma medications. Asthma management, as with management of all pediatric conditions, must also factor in the impact of adverse social determinants and health disparities. Broadly, the pandemic has also served as a call to resource stewardship and innovation and allowed practitioners to consider how this may impact asthma care moving forward.

As of October 12, 2021 there have been over 238 million cases of COVID-19 worldwide, 65 and over 4.8 million deaths. 1 In the United States, there have been more than 44 million cases 66 and more than 715,000 deaths to date. While the impact of the global pandemic has been 67 mitigated with mass international vaccination efforts, it remains forefront on the mind of 68 clinicians and families across the globe. 69

The pandemic has had a broad direct and indirect impact on children and their families. 70

While children infected with COVID-19 have a better prognosis than adults 2 and severe illness is 71 less common, 3 severe illness when it occurs can be significant among those admitted to hospital 72 and is predicated by pre-existing comorbidities. 3 Data from the Centers for Disease Control and 73

Prevention (CDC) has demonstrated that among the 96% of COVID-19 cases where age was 74 known, only 8.1% was among children <18 years of age. 4 However, morbidity can be high and 75 there are racial and ethnic disparities in outcomes. 5 

While in general preschool and school-aged children were at low risk of a direct impact 77 of COVID-19 during the early waves of the pandemic, 6 an increase in variants of concern has 78 resulted in the possibility of increasing transmissibility rates to children as well as the possibility 79 of increased morbidity and mortality. 7 In addition, there is a rising recognition of other long-term 80 complications being seen in the pediatric population-such as long-COVID and multisystem 81 inflammatory syndrome in children (MIS-C). 8,9 82 With the fall return to school, for families of children with asthma, as with families 83 overall, there is significant concern about ensuring the safety and security of children. 84 J o u r n a l P r e -p r o o f Specifically, there are concerns related to the risk that asthma poses to COVID-19 severity, and 85 how broad public health measures impact children with asthma at school. Few articles have 86 synthesized an approach to school-based management among children with underlying 87 conditions such as asthma, who may be at realor perceivedincreased risk. As a result, the 88 focus of this article is to review school asthma care during the pandemic (Figure 1) . 89 90

A major factor in parental comfort with school attendance among children with asthma is 92 their risk should they acquire COVID-19 and in particular whether asthma places children at 93 higher risk of severe COVID-19 outcomes. There are specific underlying chronic medical 94 conditions that increase the risk of severe COVID-19 outcomes in children. These include 95 obesity, chronic lung disease, neurodevelopmental disorders and epilepsy, immunodeficiency, 96 and older aged children. 10 97 While children with chronic lung disease are more likely to have severe or critical 98 COVID-19, asthma has in general been an exception. 4,6,11-16 In general, those with asthma are 99 thought to be at low risk of COVID19 severe outcomes. 17 A national prospective Canadian study 100 of 264 children admitted to hospital with COVID-19 infection found that while 39.3% of those 101 children admitted had at least one comorbidity including chronic lung disease, asthma was an 102 exception. 6 A retrospective review of COVID-19 infection among children with asthma noted no 103 increased COVID-19 severity independent of asthma severity and control over the year prior to 104 the pandemic. 13 In addition, a systematic review on asthma and COVID-19 in children noted no 105 significant data that childhood asthma constitutes a risk factor for COVID infection or severity. 18 106 While one report from the CDC found 11.5% of children with data had "chronic lung diseases 107 J o u r n a l P r e -p r o o f including asthma" and one tertiary hospital reported asthma in 23.9% of children hospitalized for 108 19 other studies have suggested perhaps even a protective risk associated with 109 atopy. 20,21 It has been demonstrated that downregulation of ACE2 expression on target cells 110 (including in the lungs) due to Th2 cytokines may actually reduce the risk of COVID-19 111 infection in atopic children. 20,21 112

There is a concern that a rise in asthma exacerbations will be seen over the fall and spring 113 this year however this was not noted during the first three waves of the pandemic. 13,22-26 A study 114 on asthma-related Emergency Department (ED) utilization in a high-volume US children's 115 hospital found, for the year 2020, a dramatic reduction in asthma-related ED use (compared to 116 the prior four years) that was significantly below historical seasonal variation. In addition, this 117 pattern of a dramatic reduction was observed for all levels of triage acuity. 25 There is firm evidence that masks do not exacerbate underlying lung conditions 32, 33 A 142 cohort study of 47 infants and young children noted that surgical face masks were not associated 143 with any changes in respiratory parameters nor clinical signs of respiratory distress. 34 A recent 144 scoping review on the impact of masks on cardiorespiratory response to exercise found that 145 while subjective sense of dyspnea may be increased with mask wearing, the objective effects on 146 work of breathing, blood gases, and other physiological parameters are minimal with no sex-147 based or age-based differences detected. 35 It has been noted by multiple international 148 organizations, including the Canadian Thoracic Society, that there is "NO evidence that wearing 149 a face mask will exacerbate (cause a 'flare up' of) an underlying lung condition. 32 In fact, the 150 opposite may in fact be true. There is emerging evidence that wearing a face mask at school, and 151 in other public places, can reduce spread of other common respiratory infectionssuch as RSV 152 and influenzathat are frequent causes of asthma exacerbations and might reduce the risk of 153 viral-triggered asthma exacerbations at school in children. 36 In conclusion, asthma is not an 154 indication for a mask exemption in schools. Another common concern is the use of asthma medications such as inhaled 253 corticosteroids (ICS) and biologics, and whether the vaccine can be given while on these 254 medications. Studies have shown the vaccine to be safe and well tolerated even if on asthma 255 biologic therapy or steroid (whether oral or inhaled) therapy, although less data is available for 256 the pediatric population. 63, 76 It is recommended that the COVID-19 vaccine and an asthma 257 biologic not be given the same day (to differentiate the inciting agent should a reaction occur). 77 are considered in the approach to a family with asthma both during, and after, the pandemic. 294

Broadly, the pandemic has also served as a call to resource stewardship and innovation 295 and allowed practitioners to consider how this may impact asthma care moving forward. 102 One 296 such example is step-up or step-down therapy. While remaining on current asthma medications is 297 generally recommended, little guidance exists on how to stratify risk during the pandemic, and 298 little guidance is specific to children or adolescents. For step-down therapy a stratification based 299 on atopic status, baseline risk, and seasonality has been proposed. 103 Another example of innovative provision of care is the use of virtual care and telehealth 306 visits, which has emerged as an opportunity to improve access, reduce health disparities, and 307 prevent potential viral exposure in clinical settings during the pandemic. 102 A study of children 308 with asthma residing in two remote locations who were offered the choice of an in-person or 309 telemedicine session noted comparable asthma control between the two visit types, with high 310 family satisfaction among those who chose the telemedicine encounter. 106 School-based 311 telemedicine interventions have also been studied and are a novel approach to ongoing asthma 312 care especially among underserved families, including those living in remote locations. 107,108 A 313 J o u r n a l P r e -p r o o f school-based telemedicine approach would reduce school absence, reduce parental leave, and 314 allow the potential for application of digital health for monitoring exacerbations and adherence 315 to asthma medications. 107,108 316 317

There is no evidence that asthma increases the risk of severe COVID-19 outcomes nor 319 that COVID-19 causes severe asthma exacerbations among school-aged children. Asthma is not 320 an indication for a mask exemption, nor for a COVID-19 vaccine exemption. It is also not 321 necessarily an indication for consideration of virtual learning. Asthma management consists of 322 remaining on current asthma medications, although step up or step down therapy could be 323 considered based on circumstances. More broadly, asthma management during the pandemic 324 must factor in other comorbidities that can worsen asthma control -such as obesity -as well as 325 more broadly the impact of adverse determinants of health. Finally, unprecedented times call for 326 unprecedented change, and this is being seen in the approach to home-based and virtual care. 327 328

Johns Hopkins Coronavirus Resource Center

332 COVID-19 in 7780 pediatric patients: A systematic review

335 Characteristics and Outcomes of Children With Coronavirus Disease

Infection Admitted to US and Canadian Pediatric Intensive Care Units

Hospitalization Rates and Characteristics of Children Aged <18 Years 341 Hospitalized with Laboratory-Confirmed COVID-19 -COVID-NET, 14 States

Characteristics of children 345 admitted to hospital with acute SARS-CoV-2 infection in Canada in 2020

Association medicale Can

Emerging SARS-CoV-2 variants of concern and potential 348 intervention approaches

CPS Position Statment: COVID-19 vaccine for children

Asthma and COVID-19: a 355 systematic review

Is asthma a risk factor for coronavirus disease-2019 worse 358 outcomes? The answer is no, but …

Impact of the COVID-19 pandemic in children with allergic 361 asthma

Children with Covid-19 in Pediatric Emergency 363 Departments in Italy

Childhood severe acute respiratory syndrome, 366 coronavirus infections and asthma

SARS-CoV-2

The association between COVID-19 and asthma: A systematic 370 review and meta-analysis

Asthma and COVID-19 in children: A systematic review and 373 call for data

Children -United States

COVID-19 in children: what did we learn from the first wave? Paediatr Child Heal

COVID-19 and Asthma: Reflection During the Pandemic

COVID-19 and Asthma

Association 385 of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2

Initial effects of the 390 COVID-19 pandemic on pediatric asthma emergency department utilization

The Impact of Coronavirus Disease

Pediatric Asthma in the United States

The ongoing impact of COVID-19 on 395 asthma and pediatric emergency health-seeking behavior in the Bronx, an epicenter. Am 396

Pediatric Asthma Health Care Utilization, Viral Testing, and Air Pollution Changes During 399 the COVID-19 Pandemic

Potential resurgence of respiratory 402 syncytial virus in Canada. C Can Med Assoc J = J l'Association medicale Can

Mask adherence 405 and rate of COVID-19 across the United States

Mask Exemptions During the COVID-19 Pandemic-A New Frontier 407 for Clinicians

Canadian Thoracic Society recommendations regarding the use of face masks by the 410 public during the SARS-CoV-2 (COVID-19) pandemic

Assessment of 417 Respiratory Function in Infants and Young Children Wearing Face Masks During the 418 COVID-19 Pandemic

Face 420 Masks and the Cardiorespiratory Response to Physical Activity in Health and Disease

Managing Asthma during COVID-19: An Example for Other 424 Chronic Conditions in Children and Adolescents

Asthma in patients with 426 suspected and diagnosed coronavirus disease

AAAAI: School Attendance, Asthma and COVID-19

Differentiation 432 symptoms from allergic rhinitis and common cold: An ARIA-433 EAACI-GA(2) LEN consensus

Managing Asthma during Coronavirus Disease-2019: An Example 435 for Other Chronic Conditions in Children and Adolescents

School Attendance, Asthma Risk, and COVID-19 in 438 Children

Pediatric asthma and COVID-19: The 440 known, the unknown, and the controversial

Transmission of SARS-CoV-2 444 in children aged 0 to 19 years in childcare facilities and schools after their reopening in 445

Infectivity of severe acute 447 respiratory syndrome coronavirus 2 in children compared with adults. C Can Med Assoc 448 J = J l'Association medicale Can

Allergy and asthma 455 in children and adolescents during the COVID outbreak: What we know and how we 456 could prevent allergy and asthma flares

The Globe and Mail: School shutdowns have put children up to eight months behind in 460 reading, research indicates

Impact of school closures for COVID-19 on the US health-care 470 workforce and net mortality: a modelling study

Mental health effects of school closures during COVID-19

COVID-19 and the impact of social determinants of health

Potential effects of 479 COVID-19 school closures on foundational skills and Country responses for mitigating 480 learning loss

Safety and 483 Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of 485 the mRNA-1273 SARS-CoV-2 Vaccine

MMWR: Acceptability of Adolescent COVID-19 Vaccination Among Adolescents and 492 Parents of Adolescents -United States

COVID-19 vaccines: addressing hesitancy in 495 young people with allergies

The Risk of Allergic 497 Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A 498 Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus 499 Approach

Adverse 501 reactions to vaccines practice parameter 2012 update

Safety Evaluation 504 of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate 505 Reactions to the First Dose

Safe 507 administration of the Pfizer-BioNtTech COVID-19 vaccine following an immediate 508 reaction to the first dose

Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: Don't give up on the second 511 dose!

Annals of allergy, asthma & immunology : official publication of the American 514 College of Allergy, Asthma, & Immunology. 2021

First-Dose mRNA 516 COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing

Polyethylene glycol and polysorbate 519 skin testing in the evaluation of coronavirus disease 2019 vaccine reactions

Annals of allergy, asthma & immunology : official publication of the American 521 College of Allergy, Asthma, & Immunology. 2021. p. 735-8. 522 74. The Advisory Committee on Immunization Practices' Interim Recommendation for

Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12-15 Years -United States

COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety

ACAAI: COVID-19 and asthma: What you need to know moving forward

CDC: How to Talk with Patients Who Are Immunocompromised

Targeting COVID-19 Vaccine Hesitancy in Minority Populations 540 in the US: Implications for Herd Immunity

Factors 542 Associated With US Adults' Likelihood of Accepting COVID-19 Vaccination

Inhaled Corticosteroids 545 and Respiratory Infections in Children With Asthma: A Meta-analysis

Factors 548 associated with COVID-19-related death using OpenSAFELY

Inhaled corticosteroids: A rapid review of the evidence for 550 treatment or prevention of COVID-19

-a-rapid-review-of-the-evidence-for-treatment-or-prevention-of-covid-19 554 85. AAAAI: Asthma and COVID19

Transmission of Corona Virus by Nebulizer-a serious, underappreciated risk! 562

Food Insecurity and Pediatric Obesity: a Double 564

Whammy in the Era of COVID-19

Physical 567 activity behaviour and screen time in Dutch children during the COVID-19 pandemic: 568 Pre-, during-and post-school closures

BMI status and associations 570 between affect

Factors Associated With COVID-19 Disease Severity in US Children and Adolescents

Underlying 576 Medical Conditions Associated With Severe COVID-19 Illness Among Children

The impact of obesity on immune function in pediatric asthma

The impact of childhood obesity on morbidity 582 and mortality in adulthood: a systematic review

The Impact of Childhood and Adolescent Obesity on Cardiovascular 585 Risk in Adulthood: a Systematic Review

Child poverty, 587 food insecurity, and respiratory health during the COVID-19 pandemic

The Impact of Social Determinants of 590 Health on Children with Asthma

Urban minority 592 children with asthma: substantial morbidity, compromised quality and access to 593 specialists, and the importance of poverty and specialty care

Racial and ethnic disparities in medical and dental health, 595 access to care, and use of services in US children

What the COVID-19 Pandemic Can 597 Teach Us About Resource Stewardship and Quality in Health Care

Ongoing asthma management in children during the COVID-19 600 pandemic: to step down or not to step down?

Health and 602 Economic Outcomes of Home Maintenance Allergen Immunotherapy in Select Patients 603 with High Health Literacy during the COVID-19 Pandemic: A Cost-Effectiveness Analysis 604 During Exceptional Times

Estimation of 606 Health and Economic Benefits of Clinic Versus Home Administration of Omalizumab

Telemedicine is as effective as in-person 609 visits for patients with asthma

Implementing Telehealth in Pediatric Asthma. Pediatr Clin North 612 Am

School-Based Telemedicine for Asthma Management

There is no consistent way to differentiate asthma from COVID-19. COVID-19 testing is the only way to differentiate infection from allergic symptoms including asthma and rhinitis at the present time. 

Adolescents with asthma and other allergic conditions would not qualify for a vaccine exemption in the absence of a history of a severe reaction to the first dose of the COVID-19 vaccine.

Multiple international organizations recommend remaining on prescribed asthma medications including inhaled corticosteroids and biologics during COVID-19.

Asthma has not thus far emerged as a risk factor for more severe COVID-19 outcomes